TERN-701
Chronic Myeloid Leukemia (CML)
Phase 3Active; CARDINAL trial enrolling
Key Facts
Indication
Chronic Myeloid Leukemia (CML)
Phase
Phase 3
Status
Active; CARDINAL trial enrolling
Company
About Terns Pharmaceuticals
Terns Pharmaceuticals is a publicly traded, clinical-stage biotech company with a mission to advance transformative medicines by reimagining known biology. Its core strategy involves selecting de-risked, clinically validated targets and applying innovative medicinal chemistry to develop potentially best-in-class small-molecule drugs. The company's most significant achievement is the advancement of TERN-701 for CML, which has culminated in a definitive acquisition agreement with Merck, validating its platform and pipeline. Terns operates with a focused, agile team and a culture designed to accelerate development timelines in high-need therapeutic areas.
View full company profileTherapeutic Areas
Other Chronic Myeloid Leukemia (CML) Drugs
| Drug | Company | Phase |
|---|---|---|
| XS003 (nilotinib) | Xspray Pharma | NDA Submitted |
| Scemblix® (asciminib) | Novartis | Approved / Lifecycle |
| ELVN-001 | Enliven Therapeutics | Phase 1b |
| BCR-ABL1 (p210) Monitoring Assay | Sniper Medical Technologies | Commercial |